Search

Your search keyword '"Cameron, Michael C."' showing total 45 results

Search Constraints

Start Over You searched for: Author "Cameron, Michael C." Remove constraint Author: "Cameron, Michael C."
45 results on '"Cameron, Michael C."'

Search Results

3. A review of non-pharmacologic approaches to enhance the patient experience in dermatologic surgery

5. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

6. Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.

8. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)

9. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

10. Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus

14. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial

16. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis:Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial

26. 27590 Abrocitinib in the treatment of moderate-to-severe atopic dermatitis refractory to dupilumab treatment: An analysis of JADE-EXTEND, a phase 3 long-term extension study

27. 27533 Comparative efficacy and safety of systemic therapies used in adult and adolescent moderate-to-severe atopic dermatitis (AD): A systematic literature review (SLR) and network meta-analysis (NMA)

30. 15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial

35. Basal cell carcinoma

37. Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and prevention.

38. Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations.

39. ASK THE EXPERTS.

41. Stretching capital dollars - build it yourself!

42. Cutaneous collagenous vasculopathy.

43. Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review.

44. Chronic Tender Ulcers on the Calf and Both Forearms.

45. Inflamed Actinic Keratoses After Pemetrexed.

Catalog

Books, media, physical & digital resources